Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics
←Back to story

Capricor Drops After FDA Again Rejects Muscular Dystrophy Drug

BloombergView source article

Part of story

FDA rejects Capricor's Duchenne muscular dystrophy cell therapy for second time

The FDA declined to approve Capricor Therapeutics' deramiocel cell therapy for Duchenne muscular dystrophy, citing significant issues with trial data reliability. This is the second rejection for the treatment, dealing a major blow to the company.

Nov 20, 2026·4 sourcesGenetic diseasesStock market performanceFDA drug approvalClinical trial transparencyRare diseasesDrug Policy, Pricing & ApprovalCorporate layoffsClinical trial design
FDA rejects Capricor's Duchenne muscular dystrophy cell therapy for second time
00

Other sources for this story

Reuters

Capricor's Duchenne treatment fails to get FDA approval, shares sink | Reuters

STAT News

FDA rejects Capricor Therapeutics' Duchenne therapy, a decision that was a long time coming

Endpoints

Capricor's Duchenne therapy is rejected again, as FDA cites significant issues with trial